TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

E L Mayer,V Abramson,R Jankowitz, C Falkson,P K Marcom,T Traina,L Carey,M Rimawi, J Specht, K Miller, V Stearns,N Tung,C Perou,A L Richardson, K Componeschi,L Trippa,Z Tan-Wasielewski,K Timms, I Krop,A C Wolff,E P Winer

Annals of Oncology（2020）

引用 46|浏览46

暂无评分

摘要

•This trial prospectively evaluated the predictive capacity of the HRD biomarker for pathologic response in early TNBC.•Pathologic responses to preoperative cisplatin or taxane monotherapy in germline BRCA1/2 wild-type TNBC were similar.•HRD score was not predictive of pathologic response to either cisplatin or paclitaxel chemotherapy.•HRD testing cannot be recommended as a tool to select chemotherapy agents in the management of early-stage TNBC.

查看译文

关键词

Triple-negative breast cancer (TNBC),cisplatin,paclitaxel,neoadjuvant,preoperative,HRD

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要